Study of E7389 Liposomal Formulation in Participants With Solid Tumor
← catalyst calendarSponsored by Eisai Co., Ltd. (industry) · 4523.T — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
140estimated
Sites
12
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-08-18 | actual | When the study began enrolling |
| Primary completion | 2018-07-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2017-07-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumor
Intervention
- Drug: E7389-LF
Primary outcome
what the primary-completion date above is the date OFMaximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF)
measured Cycle 1 (21 days): Schedule 1; Cycle 1 (28 days): Schedule 2
Publications
- PMID 35500404 — linked by the registry
- PMID 35180771 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed